New registry aims to decode MRD testing in rare, aggressive breast cancer
NCT ID NCT06966050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a registry that collects information from 200 people with stage III or IV inflammatory breast cancer (IBC). Participants fill out a quality-of-life questionnaire and provide blood samples for MRD testing. The goal is to gather data on how MRD test results relate to surgery and long-term outcomes. No new treatment is being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors better understand how MRD testing predicts outcomes in inflammatory breast cancer, potentially guiding future treatment decisions.
- What could go wrong
- This is an observational registry, not a treatment trial. It collects data only and does not test a new therapy, so it cannot directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?